Haloperidol for Treatment of ICU Delirium - Progress or Setback?
NEJM 387:2464-2465, Marcantonio,E.R., 2022
Critical Illness Myopathy
Muscle Nerve 23:1785-1788, Lacomis,D.,et al, 2000
Tenecteplase Versus Standard of Care for Minor Ischaemic Stroke with Proven Occlusion (TEMPO-2): A Randomised, Open Label, Phase 3 Superiority Trial
Lancet 403:2597-2605, Coutts,S.B.,et al, 2024
Management of Possible Multiple Sclerosis
NEJM 388:2195-2190, , 2023
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Management of Anticoagulants in Patients Undergoing Endoscopic Procedure
www.UptoDate.com, Dec, Kamath, P.S., 2018
Diagnosis of Multiple Sclerosis: Progress and Challenges
Lancet 389:1336-1346, Brownlee, W.J.,et al, 2017
Infective Endocarditis
Lancet 387:882-893, Cahill, T.J. & Prendergast, B.D., 2016
Complementary and Alternative Medicine in Multiple Sclerosis
Neurol 82:e103-e104, Fox, R.J., 2014
Early Transfer of Patients with Stroke to Comprehensive Centers is Necessary
Stroke 45:3748-3749,3752, Sheth, K.N., 2014
Early Transfer of Patients with Stroke to Comprehensive Stroke Centers is not Necessary
Stroke 45:3750-3751,3752, Langhorne, P., 2014
Management of Antithrombotic Therapy in Patients Undergoing Invasive Procedures
NEJM 368:2113-2124, Baron, T.,et al, 2013
The Types of Neurological Deficits Might Not Justify Withholding Treatment in Patients with Low Total National Institutes of Health Stroke Scale Scores
Stroke 43:782-786,625, Leira,E.C.,et al, 2012
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
No-Go to Tissue Plasminogen Activator for Transient Ischemic Attack
Stroke 41:3005-3006, 3007, Liebeskind,D.S., 2010
Pro: Intravenous Tissue Plasminogen Activator in Stroke Patients With Rapid, Complete Recovery During Evaluation (Transient Ischemic Attack) and Evidence of Middle Cerebral Artery Occlusion
Stroke 41:3003-3004, 3007, K�hrmann,M. &Schellinger,P.D., 2010
Strokes After Cardiac Surgery and Relationship to Carotid Stenosis
Arch Neurol 66:1091-1096, 1062, Li,Y.,et al, 2009
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Cerebral Sinovenous Thrombosis in the Neonate
Arch Neurol 63:405-409, Fitzgerald,K.C.,et al, 2006
Treatment of Low Back Pain by Acupressure and Physical Therapy: Randomised Controlled Trial
BMJ 332:696-698,680, Hsieh,L.L.-C.,et al, 2006
Most Patients With Multiple Sclerosis or a Clinically Isolated Demyelinating Syndrome Should be Treated at the Time of Diagnosis
Arch Neurol 63:614-619, Frohman,E.M.,et al, 2006
Not Every Patient With Multiple Sclerosis Should Be Treated at Time of Diagnosis
Arch Neurol 63:611-619, Pittock,S.J.,et al, 2006
Accuracy of Magnetic Resonance Imaging for the Diagnosis of Multiple Sclerosis: Systematic Review
BMJ 332:875-878, Whiting P.,et al, 2006
Central Nervous System Injury Associated with Cardiac Surgery
Lancet 368:694-703, Newman,M.F.,et al, 2006
Simultaneous Carotid Endarterectomy and Coronary Artery Bypass Surgery in Canada
Neurol 64:1435-1437,1332, Hill,M.D.,et al, 2005
Patent Foramen Ovale Closure Devices
JAMA 294:366-369, Maisel,W.H.&Laskey,W.K., 2005
Patent Foramen Ovale and Recurrent Stroke: Closure is the Best Option: No
Stroke 35:804-805,806, Tong,D.C. &Becker,K.J., 2004
Patent Foramen Ovale and Recurrent Stroke: Closure is the Best Option: Yes
Stroke 35:803-804,806, Furlan,A.J., 2004
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Early Carotid Endarterectomy After Acute Stroke
J Vasc Surg 39:148-154, Paty,P.S.K.,et al, 2004
Incidence and Clinical Course of Thrombus Formation on Atrial Septal Defect and Patent Foramen Ovale Closure Devices in 1,000 Consecutive Patients
J Am Coll Cardiol 43:302-309, Krumsdorf,U.,et al, 2004
Interferons in Relapsing Remitting Multiple Sclerosis: A Systematic Review
Lancet 361:545-552, Filippini,G.,et al, 2003
The Utility of MRI in Suspected MS, Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 61:602-611,596, Frohman,E.M.,et al, 2003
Continuation of Medically Necessary Aspirin and Warfarin During Cutaneous Surgery
Mayo Clin Proc 78:1392-1396, Otley,C.C., 2003
Stroke is Best Managed by a Neurologist: Battle of the Titans
Stroke 34:2764,2765, Lees,K.R., 2003
Stroke is Best Managed by Neurologists
Stroke 34:2763,2765, Caplan,L., 2003
Hospital and Surgeon Determinants of Carotid Endarterectomy Outcomes
Arch Neurol 59:1877-1881,1866, Feasby,T.E.,et al, 2002
Management of Acute Optic Neuritis
Lancet 360:1953-1962, Hickman,S.J.,et al, 2002
Intraarterial Thrombolysis: Ready for Prime Time?
AJNR 22:55-58, Executive Committee of the ASITN, 2001
Measurement of Antibodies to Interferon Beta in Patients With Multiple Sclerosis
Arch Neurol 58:1299-1300,1301, Pachner,A.R., 2001
The Significance of Neutralizing Antibodies in Patients With Multiple Sclerosis Treated With Interferon Beta
Arch Neurol 58:1297-1298,1301, Rice,G., 2001
Trauma Does Not Precipitate Multiple Sclerosis
Arch Neurol 57:1077-1078, Cook.S.D., 2000
Trauma to the Central Nervous System May Result in Formation or Enlargement of Multiple Sclerosis Plaques
Arch Neurol 57:1074-1076,1078, Poser,C.M., 2000
Multiple Sclerosis--From Probable to Definite Diagnosis
Arch Neurol 57:974-979,930, Achiron,A. & Barak,Y., 2000
Fibromyalgia Syndrome a Decade Later
Arch Int Med 159:777-785, Goldenberg,D.L., 1999
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Population Based Cost Utility Study of Interferon Beta-1b in Secondary Progressive Multiple Sclerosis
BMJ 319:1529-1533, Forbes,R.B.,et al, 1999